Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Bradykinesia Market Growth in 2025?

The market for bradykinesia has witnessed fast-paced enlargement over the past few years. By 2025, it is projected to reach $3.41 billion, up from $3 billion in 2024, reflecting a compound annual growth rate (CAGR) of 13.6%. The significant growth during the historical period is largely a result of the surge in movement disorder clinics, the increased post-stroke motor complication burden, higher incidence of inherited neurodegenerative disorders, the rise in clinical trials for treatments related to bradykinesia, and the expansion of healthcare infrastructure.

What Is the Forecast for the Bradykinesia Market Size Through 2029?

In the coming years, the bradykinesia market is projected to undergo swift expansion. By 2029, it is expected to reach a value of $5.64 billion, with a compound annual growth rate (CAGR) of 13.4%. Several factors will drive this growth during the predicted period, including the worldwide increase in Parkinson’s disease cases, a rise in neurological disorder incidences, an aging demographic susceptible to neurodegenerative diseases, greater awareness and early detection of bradykinesia, and the broadening of diagnostic capabilities in developing economies. Key trends for the forecasted period include advances in neurostimulation devices, the creation of new drug delivery systems, the application of wearable technology for movement tracking and symptom monitoring, the rise of telehealth and distant neurological consultations, and the progress in gene therapy that targets motor dysfunction.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24487&type=smp

What are the Key Market Players in Bradykinesia Market and How They’re Evolving?

Major companies operating in the bradykinesia market are AbbVie Inc., Novartis AG, Medtronic Plc, Eli Lilly and Company, Otsuka Pharmaceutical Co. Ltd., Biogen Inc., Eisai Co. Ltd., Kyowa Kirin Co. Ltd., Lundbeck AS, Amneal Pharmaceuticals Inc., Orion Corporation, Acadia Pharmaceuticals Inc., Acorda Therapeutics Inc., Denali Therapeutics Inc., Adamas Pharmaceuticals, Impel NeuroPharma, Annovis Bio Inc., BlueRock Therapeutics LLC, NeuroDerm Ltd., Cerevance LLC, Sage Therapeutics, Anavex Life Sciences Corp., Inhibikase Therapeutics Inc.

What Are the Primary Growth Drivers in the Bradykinesia Market?

The growing occurrence of neurological conditions is expected to stimulate the expansion of the bradykinesia market in the future. Neurological disorders, which can impact the brain, spinal cord, or nerves and result in abnormal movement, sensation, or cognition, are becoming more common because of global aging. As the brain ages, the likelihood of nerve system disorders increases. The rising incidence of such disorders is thus sparking demand for bradykinesia therapies. Most of these conditions are characterised by slower or decreased motion, necessitating a increased need for treatments that can enhance motor functions. For example, the American Parkinson Disease Association (APDA), a US-based advocacy organization, reported in January 2023 that the number of individuals with Parkinson’s disease is expected to reach 1.3 million by 2030. This suggests a consistent increase in diagnosed cases. As a result, the growing prevalence of neurological disorders is set to escalate the growth of the bradykinesia market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24487&type=smp

What Are the Leading Segments in the Global Bradykinesia Industry?

The bradykinesia market covered in this report is segmented –

1) By Combination Therapy: Mono-Therapy, Combination Therapy

2) By Disease Severity: Early-Stage Parkinson’s, Advanced-Stage Parkinson’s

3) By Symptom Management: Bradykinesia, Tremors, Rigidity

Subsegments:

1) By Mono-Therapy: Levodopa, Dopamine Agonists, MAO-B Inhibitors, Anticholinergics, Amantadine

2) By Combination Therapy: Levodopa And Carbidopa, Levodopa And COMT Inhibitors, Dopamine Agonists And MAO-B Inhibitors, Levodopa And MAO-B Inhibitors, Triple Therapy

What Are the Key Market Trends in the Bradykinesia Industry?

Leading entities in the bradykinesia market are fostering innovation by striving to produce novel solutions like sublingual therapies. These treatments are particularly beneficial for patients struggling with swallowing pills and involve placing the medication under the tongue for quick absorption into the bloodstream via the mucous membranes. A prime example is from March 2023, when Portugal’s Parkinson’s disease treatment producer, BIAL, introduced KYNMOBI (apomorphine hydrochloride) to cater to the on-demand help for OFF episodes related to Parkinson’s disease. Such episodes are characterized by an escalation or recurrence of issues like bradykinesia, tremor, and rigidity when standard drugs cease to be effective. The apomorphine hydrochloride’s sublingual film formulation presents a quick-acting solution that dissolves under the tongue. This non-ergoline dopamine agonist helps tackle sudden shifts in motor symptoms and is usually well-received. Moreover, it aids continuous symptom management during OFF periods.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/bradykinesia-global-market-report

What Is the Regional Outlook for the Bradykinesia Market?

North America was the largest region in the bradykinesia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bradykinesia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24487

This Report Delivers Insight On:

1. How big is the bradykinesia market, and how is it changing globally?

2. Who are the major companies in the bradykinesia market, and how are they performing?

3. What are the key opportunities and risks in the bradykinesia market right now?

4. Which products or customer segments are growing the most in the bradykinesia market?

5. What factors are helping or slowing down the growth of the bradykinesia market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model